SG Americas Securities LLC Invests $664,000 in CG Oncology, Inc. (NASDAQ:CGON)

SG Americas Securities LLC acquired a new position in CG Oncology, Inc. (NASDAQ:CGON) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 17,595 shares of the company’s stock, valued at approximately $664,000.

A number of other institutional investors also recently bought and sold shares of the stock. Ameritas Investment Partners Inc. bought a new position in shares of CG Oncology in the first quarter worth about $102,000. California State Teachers Retirement System bought a new stake in CG Oncology during the 1st quarter worth approximately $103,000. Profund Advisors LLC purchased a new position in CG Oncology during the second quarter valued at approximately $300,000. BNP Paribas Financial Markets bought a new position in shares of CG Oncology in the first quarter worth approximately $492,000. Finally, Capstone Investment Advisors LLC purchased a new stake in shares of CG Oncology in the first quarter worth $806,000. 26.56% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Roth Capital raised shares of CG Oncology to a “strong-buy” rating in a report on Tuesday, August 27th. Bank of America reiterated a “buy” rating and set a $65.00 target price on shares of CG Oncology in a research report on Tuesday, October 8th. Roth Mkm started coverage on CG Oncology in a report on Tuesday, August 27th. They issued a “buy” rating and a $65.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of CG Oncology in a report on Tuesday, September 17th. Finally, Royal Bank of Canada assumed coverage on shares of CG Oncology in a report on Monday, September 23rd. They issued an “outperform” rating and a $66.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $64.43.

Insiders Place Their Bets

In other CG Oncology news, Director Hong Fang Song sold 650,455 shares of the company’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $35.36, for a total transaction of $23,000,088.80. Following the sale, the director now directly owns 586,982 shares in the company, valued at $20,755,683.52. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

CG Oncology Trading Up 4.7 %

NASDAQ CGON opened at $36.09 on Monday. The stock has a 50 day moving average price of $35.89 and a 200-day moving average price of $35.01. CG Oncology, Inc. has a one year low of $25.77 and a one year high of $50.23.

CG Oncology (NASDAQ:CGON) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.14. The business had revenue of $0.11 million during the quarter. On average, sell-side analysts predict that CG Oncology, Inc. will post -1.47 earnings per share for the current fiscal year.

CG Oncology Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.